Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients

References

• Mihm MC, Jr., Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: A histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996; 74(1):43-47; PMID: 8569196
   PubMed Web of Science ®Google Scholar
• Dalerba P, Maccalli C, Casati C, Castelli C, Parmiani G. Immunology and immunotherapy of colorectal cancer. Crit Rev Oncol Hematol 2003; 46(1):33-57; PMID: 12672517; https://doi.org/10.1016/S1040-8428(02)00159-2
   PubMed Web of Science ®Google Scholar
• Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH. Immune infiltration in human tumors: A prognostic factor that should not be ignored. Oncogene 2010; 29(8):1093-102; PMID: 19946335; https://doi.org/10.1038/onc.2009.416
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Fridman WH, Galon J. The prognostic impact of anti-cancer immune response: A novel classification of cancer patients. Semin Immunopathol 2011; 33(4):335-40; PMID: 21461991; https://doi.org/10.1007/s00281-011-0264-x
   PubMed Web of Science ®Google Scholar
• Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pagès F et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011; 71(4):1263-71; PMID: 21303976; https://doi.org/10.1158/0008-5472.CAN-10-2907
   PubMed Web of Science ®Google Scholar
• Fridman WH, Dieu-Nosjean MC, Pages F, Cremer I, Damotte D, Sautès-Fridman C, Galon J. The immune microenvironment of human tumors: General significance and clinical impact. Cancer Microenviron 2013; 6(2):117-22; PMID: 23108700; https://doi.org/10.1007/s12307-012-0124-9
   PubMedGoogle Scholar
• Angell H, Galon J. From the immune contexture to the Immunoscore: The role of prognostic and predictive immune markers in cancer. Curr Opin Immunol 2013; 25(2):261-67; PMID: 23579076; https://doi.org/10.1016/j.coi.2013.03.004
   PubMed Web of Science ®Google Scholar
• Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases–elimination, equilibrium and escape. Curr Opin Immunol 2014; 27:16-25; PMID: 24531241; https://doi.org/10.1016/j.coi.2014.01.004
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Woo SR, Zha Y, Spaapen R, Zheng Y, Corrales L, Spranger S. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol 2013; 25(2):268-76; PMID: 23579075; https://doi.org/10.1016/j.coi.2013.02.009
   PubMed Web of Science ®Google Scholar
• Nelson D, Fisher S, Robinson B. The “Trojan Horse” approach to tumor immunotherapy: Targeting the tumor microenvironment. J Immunol Res 2014; 2014:789069; PMID: 24955376; https://doi.org/10.1155/2014/789069
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12(4):252-64; PMID: 22437870; https://doi.org/10.1038/nrc3239
   PubMed Web of Science ®Google Scholar
• Pardoll DM. Immunology beats cancer: A blueprint for successful translation. Nat Immunol 2012; 13(12):1129-32; PMID: 23160205; https://doi.org/10.1038/ni.2392
   PubMed Web of Science ®Google Scholar
• Wilden SM, Lang BM, Mohr P, Grabbe S. Immune checkpoint inhibitors: A milestone in the treatment of melanoma. J Dtsch Dermatol Ges 2016; 14(7):685-95; PMID:27373243; https://doi.org/10.1111/ddg.13012
   PubMed Web of Science ®Google Scholar
• Guennoun A, Sidahmed H, Maccalli C, Seliger B, Marincola FM, Bedognetti D. Harnessing the immune system for the treatment of melanoma: Current status and future prospects. Expert Rev Clin Immunol 2016; 12:879-93; PMID:27070898; https://doi.org/10.1080/1744666X.2016.1176529
   PubMed Web of Science ®Google Scholar
• Rajan A, Kim C, Heery CR, Guha U, Gulley JL. Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Hum Vaccin Immunother 2016; 12(9):2219-31; PMID: 27135835; https://doi.org/10.1080/21645515.2016.1175694
   PubMed Web of Science ®Google Scholar
• Xia Y, Medeiros LJ, Young KH. Immune checkpoint blockade: Releasing the brake towards hematological malignancies. Blood Rev 2016; 30(3):189-200; PMID: 26699946; https://doi.org/10.1016/j.blre.2015.11.003
   PubMed Web of Science ®Google Scholar
• Haanen JB, Robert C. Immune Checkpoint Inhibitors. Prog Tumor Res 2015; 42:55-66; PMID: 26382943; https://doi.org/10.1159/000437178
   PubMed Web of Science ®Google Scholar
• Luke JJ, Ott PA. PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma. Oncotarget 2015; 6(6):3479-92; PMID: 25682878; https://doi.org/10.18632/oncotarget.2980
   PubMed Web of Science ®Google Scholar
• Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373(13):1270-71; PMID: 26398076; https://doi.org/10.1056/NEJMc1509660
   PubMed Web of Science ®Google Scholar
• Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S, Berdelou A et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 2016; 13(8):473-86; PMID: 27141885; https://doi.org/10.1038/nrclinonc.2016.58
   PubMed Web of Science ®Google Scholar
• Antonia SJ. Moving beyond monotherapy in the immunotherapeutic arena: Prospects for combination therapies in lung cancer. Clin Adv Hematol Oncol 2016; 14(8):616-18; PMID: 27487105; https://doi.org/10.1016/S1470-2045(16)30098-5
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Marincola FM, Atkins MB. What's new in melanoma? Combination!. J Transl Med 2015; 13:213; PMID: 26141621; https://doi.org/10.1186/s12967-015-0582-1
   PubMed Web of Science ®Google Scholar
• Ascierto PA. Editorial: Combination strategies in the treatment of melanoma. Front Oncol 2016; 6:67; PMID: 27047798; https://doi.org/10.3389/fonc.2016.00067
   PubMed Web of Science ®Google Scholar
• Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: Similarities, differences, and implications of their inhibition. Am J Clin Oncol 2016; 39(1):98-106; PMID: 26558876; https://doi.org/10.1097/COC.0000000000000239
   PubMed Web of Science ®Google Scholar
• Maccalli C, Giannarelli D, Capocefalo F, Pilla L, Fonsatti E, Di Giacomo AM, Parmiani G, Maio M. Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study. Oncoimmunology 2016; 5(2):e1071007; PMID: 27057436; https://doi.org/10.1080/2162402X.2015.1071007
   PubMed Web of Science ®Google Scholar
• Deichmann M, Benner A, Bock M, Jäckel A, Uhl K, Waldmann V, Näher H. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 1999; 17(6):1891-96; PMID: 10561230; https://doi.org/10.1200/JCO.1999.17.6.1891
   PubMed Web of Science ®Google Scholar
• Weide B, Elsasser M, Buttner P, Pflugfelder A, Leiter U, Eigentler TK, Bauer J, Witte M, Meier F, Garbe C. Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. Br J Cancer 2012; 107(3):422-28; PMID: 22782342; https://doi.org/10.1038/bjc.2012.306
   PubMed Web of Science ®Google Scholar
• Maccalli C, Scaramuzza S, Parmiani G. TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors. Cancer Immunol Immunother 2009; 58(5):801-08; PMID: 19089424; https://doi.org/10.1007/s00262-008-0635-x
   PubMed Web of Science ®Google Scholar
• Paschen A, Sucker A, Hill B, Moll I, Zapatka M, Nguyen XD, Sim GC, Gutmann I, Hassel J, Becker JC et al. Differential clinical significance of individual NKG2D ligands in melanoma: Soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res 2009; 15(16):5208-15; PMID: 19671853; https://doi.org/10.1158/1078-0432.CCR-09-0886
   PubMed Web of Science ®Google Scholar
• Zhang J, Basher F, Wu JD. NKG2D ligands in tumor immunity: Two sides of a coin. Front Immunol 2015; 6:97; PMID: 25788898; https://doi.org/10.3389/fimmu.2015.00097
   PubMed Web of Science ®Google Scholar
• Chitadze G, Bhat J, Lettau M, Janssen O, Kabelitz D. Generation of soluble NKG2D ligands: Proteolytic cleavage, exosome secretion and functional implications. Scand J Immunol 2013; 78(2):120-29; PMID: 23679194; https://doi.org/10.1111/sji.12072
   PubMed Web of Science ®Google Scholar
• Paschen A, Baingo J, Schadendorf D. Expression of stress ligands of the immunoreceptor NKG2D in melanoma: Regulation and clinical significance. Eur J Cell Biol 2014; 93(1-2):49-54; PMID: 24629838; https://doi.org/10.1016/j.ejcb.2014.01.009
   PubMed Web of Science ®Google Scholar
• Baragano Raneros A, Suarez-Alvarez B, Lopez-Larrea C. Secretory pathways generating immunosuppressive NKG2D ligands: New targets for therapeutic intervention. Oncoimmunology 2014; 3:e28497; PMID: 25050215; https://doi.org/10.4161/onci.28497
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Chikumi H, Shimizu A, Takata M, Kinoshita N, Hashimoto K, Nakamoto M, Matsunaga S, Kurai J, Miyake N et al. Diagnostic and prognostic impact of serum-soluble UL16-binding protein 2 in lung cancer patients. Cancer Sci 2012; 103(8):1405-13; PMID: 22587355; https://doi.org/10.1111/j.1349-7006.2012.02330.x
   PubMed Web of Science ®Google Scholar
• Nuckel H, Switala M, Sellmann L, Horn PA, Dürig J, Dührsen U, Küppers R, Grosse-Wilde H, Rebmann V. The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia. Leukemia 2010; 24(6):1152-59; PMID: 20428196; https://doi.org/10.1038/leu.2010.74
   PubMed Web of Science ®Google Scholar
• Chitadze G, Lettau M, Bhat J, Wesch D, Steinle A, Fürst D, Mytilineos J, Kalthoff H, Janssen O, Oberg HH et al. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: Heterogeneous involvement of the “a disintegrin and metalloproteases” 10 and 17. Int J Cancer 2013; 133(7):1557-66; PMID: 23526433; https://doi.org/10.1002/ijc.28174
   PubMed Web of Science ®Google Scholar
• Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419(6908):734-38; PMID: 12384702; https://doi.org/10.1038/nature01112
   PubMed Web of Science ®Google Scholar
• El-Gazzar A, Groh V, Spies T. Immunobiology and conflicting roles of the human NKG2D lymphocyte receptor and its ligands in cancer. J Immunol 2013; 191(4):1509-15; PMID: 23913973; https://doi.org/10.4049/jimmunol.1301071
   PubMed Web of Science ®Google Scholar
• Liu G, Lu S, Wang X, Page ST, Higano CS, Plymate SR, Greenberg NM, Sun S, Li Z, Wu JD. Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis. J Clin Invest 2013; 123(10):4410-22; PMID: 24018560; https://doi.org/10.1172/JCI69369
   PubMed Web of Science ®Google Scholar
• Xiao G, Wang X, Sheng J, Lu S, Yu X, Wu JD. Soluble NKG2D ligand promotes MDSC expansion and skews macrophage to the alternatively activated phenotype. J Hematol Oncol 2015; 8:13; PMID: 25887583; https://doi.org/10.1186/s13045-015-0110-z
   PubMed Web of Science ®Google Scholar
• Jinushi M, Hodi FS, Dranoff G. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A 2006; 103(24):9190-95; PMID: 16754847; https://doi.org/10.1073/pnas.0603503103
   PubMed Web of Science ®Google Scholar
• Doubrovina ES, Doubrovin MM, Vider E, Sisson RB, O'Reilly RJ, Dupont B, Vyas YM. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol 2003; 171(12):6891-99; PMID: 14662896; https://doi.org/10.4049/jimmunol.171.12.6891
   PubMed Web of Science ®Google Scholar
• Wu J. Antibody targeting soluble NKG2D ligand sMIC refuels and invigorates the endogenous immune system to fight cancer. Oncoimmunology 2016; 5(3):e1095434; PMID: 27141357; https://doi.org/10.1080/2162402X.2015.1095434
   PubMed Web of Science ®Google Scholar
• Felix J, Cassinat B, Porcher R, Schlageter MH, Maubec E, Pages C, Baroudjian B, Homyrda L, Boukouaci W, Tamouza R et al. Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy. Int Immunopharmacol 2016; 40:466-73; PMID: 27728898; https://doi.org/10.1016/j.intimp.2016.09.030
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 2009; 15(23):7412-20; PMID: 19934295; https://doi.org/10.1158/1078-0432.CCR-09-1624
   PubMed Web of Science ®Google Scholar
• Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, Marasco A, Rivoltini L, Simeone E, Nicoletti SV et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): An open-label, single-arm phase 2 trial. Lancet Oncol 2012; 13(9):879-86; PMID: 22894884; https://doi.org/10.1016/S1470-2045(12)70324-8
   PubMed Web of Science ®Google Scholar